220 related articles for article (PubMed ID: 24260180)
1. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.
Jaisamrarn U; Castellsagué X; Garland SM; Naud P; Palmroth J; Del Rosario-Raymundo MR; Wheeler CM; Salmerón J; Chow SN; Apter D; Teixeira JC; Skinner SR; Hedrick J; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Paavonen J; Bozonnat MC; Descamps D; Struyf F; Dubin GO; Rosillon D; Baril L;
PLoS One; 2013; 8(11):e79260. PubMed ID: 24260180
[TBL] [Abstract][Full Text] [Related]
2. Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016.
Welby S; Rosillon D; Feng Y; Borys D
Expert Rev Vaccines; 2022 Mar; 21(3):407-413. PubMed ID: 34939897
[TBL] [Abstract][Full Text] [Related]
3. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
Skinner SR; Wheeler CM; Romanowski B; Castellsagué X; Lazcano-Ponce E; Del Rosario-Raymundo MR; Vallejos C; Minkina G; Pereira Da Silva D; McNeil S; Prilepskaya V; Gogotadze I; Money D; Garland SM; Romanenko V; Harper DM; Levin MJ; Chatterjee A; Geeraerts B; Struyf F; Dubin G; Bozonnat MC; Rosillon D; Baril L;
Int J Cancer; 2016 May; 138(10):2428-38. PubMed ID: 26685704
[TBL] [Abstract][Full Text] [Related]
4. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Hernandez-Avila M; Brown DR; Elbasha E; Muñoz N; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):287-96. PubMed ID: 21300618
[TBL] [Abstract][Full Text] [Related]
5. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
6. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
7. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
8. Molecular progression to cervical precancer, epigenetic switch or sequential model?
Nedjai B; Reuter C; Ahmad A; Banwait R; Warman R; Carton J; Boer S; Cuzick J; Lorincz AT
Int J Cancer; 2018 Oct; 143(7):1720-1730. PubMed ID: 29679470
[TBL] [Abstract][Full Text] [Related]
9. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
Coutlée F; Ratnam S; Ramanakumar AV; Insinga RR; Bentley J; Escott N; Ghatage P; Koushik A; Ferenczy A; Franco EL
J Med Virol; 2011 Jun; 83(6):1034-41. PubMed ID: 21503917
[TBL] [Abstract][Full Text] [Related]
10. Plasma expression of miRNA-21, - 214, -34a, and -200a in patients with persistent HPV infection and cervical lesions.
Wang H; Zhang D; Chen Q; Hong Y
BMC Cancer; 2019 Oct; 19(1):986. PubMed ID: 31646977
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
12. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K; Shabalova I; Sarian L; Naud P; Longatto-Filho A; Derchain S; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Serpa Hammes L; Podistov J; Costa S; Syrjänen S; ;
Eur J Gynaecol Oncol; 2012; 33(1):5-14. PubMed ID: 22439398
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.
Guan P; Howell-Jones R; Li N; Bruni L; de Sanjosé S; Franceschi S; Clifford GM
Int J Cancer; 2012 Nov; 131(10):2349-59. PubMed ID: 22323075
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
[TBL] [Abstract][Full Text] [Related]
16. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
[TBL] [Abstract][Full Text] [Related]
17. Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
Castellsagué X; Paavonen J; Jaisamrarn U; Wheeler CM; Skinner SR; Lehtinen M; Naud P; Chow SN; Del Rosario-Raymundo MR; Teixeira JC; Palmroth J; de Carvalho NS; Germar MJ; Peters K; Garland SM; Szarewski A; Poppe WA; Romanowski B; Schwarz TF; Tjalma WA; Bosch FX; Bozonnat MC; Struyf F; Dubin G; Rosillon D; Baril L;
BMC Infect Dis; 2014 Oct; 14():551. PubMed ID: 25927224
[TBL] [Abstract][Full Text] [Related]
18. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
19. HPV16-Related Cervical Cancers and Precancers Have Increased Levels of Host Cell DNA Methylation in Women Living with HIV.
Kremer WW; van Zummeren M; Heideman DAM; Lissenberg-Witte BI; Snijders PJF; Steenbergen RDM; Dreyer G; Meijer CJLM
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360578
[TBL] [Abstract][Full Text] [Related]
20. Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3.
Syrjänen K; Shabalova I; Naud P; Derchain S; Sarian L; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Hammes LS; Costa S; Podistov J; Syrjänen S; ; ;
Int J STD AIDS; 2011 May; 22(5):263-72. PubMed ID: 21571974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
